http://www.i-base.info/htb/index.html Not-for-profit technical review of latest treatment research and news relating to clinical management of HIV. fri, 28 nov 2008 14:15:00 GMT fri, 28 nov 2008 14:15:00 GMT   en-gb HIV i-Base and contibutors rss@i-base.org.uk rss@i-base.org.uk   http://www.i-base.info/htb/v9/htb9-11-12/48th.html We were not able to attend the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this year, which has gradually reduced its focus on HIV, although this year the meeting was combined annual IDSA meeting.     http://www.i-base.info/htb/v9/htb9-11-12/No.html Data from the NISDI Perinatal Study conducted in Argentina and Brazil suggest no association between in utero antiretroviral (ARV) exposure and congenital anomalies (CAs).   http://www.i-base.info/htb/v9/htb9-11-12/Efavirenz.html A PK study evaluated the effect of co-administration of EFV 600 mg on an ethinylestradiol (EE) and norgestimate (NGM)-containing oral contraceptive (OC). http://www.i-base.info/htb/v9/htb9-11-12/Studies.html Several posters provided information on interesting compounds in development.   http://www.i-base.info/htb/v9/htb9-11-12/Bone.html People randomised to continuous antiretroviral therapy in the SMART trial lost more bone mineral density (BMD) than those randomised to intermittent therapy, according to results of a SMART substudy analysis. [1]   http://www.i-base.info/htb/v9/htb9-11-12/Parathyroid.html A small study from Childs and colleagues from the Mount Sinai School of Medicine, New York, suggested a link between use of tenofovir and a development of secondary hyperparathyroidism that is indicative of abnormal calcium metabolism, which can result in osteopaenia and osteoporosis. This study conducted in New York City included 51 men on antiretroviral therapy. They measured blood-level of 25-hydroxyvitamin D [25(OH)-D], the active form of vitamin D, and parathyroid hormone (PTH).   http://www.i-base.info/htb/v9/htb9-11-12/Drug.html The following summaries are selected from a longer report, available with hyperlinks to the conference abstracts, from the HIV Drug Interactions web site   http://www.i-base.info/htb/v9/htb9-11-12/Single.html Results of a randomised, double-blind, placebo controlled trial in Tanzania of single high-dose oral fluconazle was reported by Omar Hamza and colleagues from Muhimbili University, Tanzania.   http://www.i-base.info/htb/v9/htb9-11-12/BHIVA.html Compared with HIV-seronegative individuals, HIV-seropositive persons may have an increased risk of infection or experience more severe disease following exposure to vaccine-preventable diseases. The positive impact of antiretroviral therapy on the natural history of HIV infection makes the formulation of HIV-specific immunisation guidelines important at this time.   http://www.i-base.info/htb/v9/htb9-11-12/OCTANE.html On 28 October 2008 the National Institute of Allergy and Infectious Disease (NIAID) in the US issued a press release in which they explain that an interim DSMB review of a large clinical trial has found LPV/r containing HAART to be significantly more effective than NVP containing HAART in women who had previously received a single dose of NVP to reduce mother to child transmission. http://www.i-base.info/htb/v9/htb9-11-12/Key.html Two papers will come to be recognised as pivotal contributions to our understanding of the mechanism of ritonavir changes in drug disposition. http://www.i-base.info/htb/v9/htb9-11-12/Control.html A free access article in the journal Clinical Infectious Diseases describes the case of an individual controlling HIV to below 50 copies/ml in the absence of treatment (classified as an “elite controller”) who became superinfected with another virus. [1]